
Clinchoice sp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Clinchoice is a global full-service contract research organization (CRO) that specializes in clinical development, post-marketing support, and functional service support for pharmaceuticals, medical devices, and consumer health products. The company conducts clinical studies, including advanced therapies like Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting solid tumors. Clinchoice provides comprehensive solutions from early clinical development through to post-approval lifecycle management across various therapeutic areas.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 3 of 6 financial statements were filed late (the longest delay 458 days for 2024).
- 2025not filed
- 202416/10/2026
- 202303/07/2024
- 202213/07/2023
- 202107/11/2022
- 202013/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
News
Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
MELBOURNE, Australia, March 23, 2026 — Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring groundbreaking health innovations and discoveries closer to patients worldwide.” Each organization brings distinct strengths to healthcare innovation, and both share […]

ClinChoice Wins the Nationwide Pharmaceutical Championship 2025 of Armenia
ClinChoice participated in the Pharmaceutical Championship 2025 in Armenia, promoting excellence and collaboration in pharmacy and was awarded the prize of ~$2,600.

ClinChoice Earns Global ISO 9001:2015 and ISO 14155:2020 Re-Certification by TÜV NORD
ClinChoice is proud to announce the successful completion and approval of its ISO 9001:2015 and ISO 14155:2020 Re-Certification by TÜV NORD.
Industry
Offer
- Clinical development
- Clinical operations
- Biometrics
- Medical monitoring
- Safety surveillance
- Regulatory affairs
- Medical writing
- Real-world evidence
Websites
- clinchoice.comYour full-service global CRO | ClinChoiceWordPress 3.7HubSpotGoogle Tag ManagerYoast SEOCloudflare
- clinchoice.co.jpトップページ - ClinChoiceWordPress 7.1Yoast SEOApache
- clinchoice.com.cnClinChoice昆翎
Job offers
The company has its own careers page: clinchoice.com/careers.
Authorized Representatives
Manner of representation
Each member of the management board independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Clinchoice S.r.l. | 1,000 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the Clinchoice S.R.L. (Italy) group, which is its direct owner.
Bank accounts
Registered as a VAT taxpayer on 2000-07-10.
23 1240 1053 1111 0010 5612 4898
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 20, 2012 | Commercial Companies Code notice | |
| Nov 7, 2011 | Merger plan |
Public aid
4 public aid cases recorded, with a total value of $386,783.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Kapadi sp. z o.o. | $7,248,714.39 | kapadi.com | ||
| Biostat sp. z o.o. | $6,243,162.72 | biostat.com.pl | ||
| Humaneva S.A. | $5,127,921.80 | humaneva.com | ||
| Brillance sp. z o.o. | $3,327,685.13 | brillance.pl | ||
| Pure Clinical sp. z o.o. | $1,676,907.27 | pureclinical.eu | ||
| Associated Medical Clinical Science Services sp. z o.o. | $1,449,035.10 | associated-medical.com.pl | ||
| 2kmm sp. z o.o. | $1,358,321.52 | 2kmm.pl | ||
| Simbec-Orion (Pol) sp. z o.o. | $631,143.10 | simbecorion.com | ||
| Scientia Cro sp. z o.o. | $607,622.19 | scientiacro.com | ||
| CTI Clinical Trial and Consulting Services Poland sp. z o.o. | $527,145.56 | ctifacts.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-04-15 | Name change (Cromsource → Clinchoice) | |
| 2012-11-16 | Address change (Lektykarska 25/20, 01-687, Warszawa → Gen. Józefa Zajączka 32, 01-510, Warszawa) | |
| 2012-03-26 | Name change (Crom Polska → Cromsource) | |
| 2007-05-08 | Share capital increase (45,000.00 PLN → 50,000.00 PLN) | |
| 2002-01-24 | Address change (Kasprowicza 151/201, 01-949, Warszawa → Lektykarska 25/20, 01-687, Warszawa) |
FAQ
Last updated: 2026-10-18